RIMA LINVILLE: Open Payments
NPI 1265674881 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$893 in 32 payments from 14 companies in 2025. Trend: 2023 $567 · 2024 $1,100 · 2025 $893
Food & beverage: $893
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $217 |
| GlaxoSmithKline, LLC. | 8 | $171 |
| Merck Sharp & Dohme LLC | 4 | $120 |
| AstraZeneca Pharmaceuticals LP | 2 | $57 |
| Novartis Pharmaceuticals Corporation | 2 | $57 |
| PFIZER INC. | 2 | $53 |
| EMD Serono, Inc. | 2 | $48 |
| Exelixis Inc. | 2 | $38 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Apellis Pharmaceuticals, Inc. | 1 | $28 |
Products named: ELAHERE, JEMPERLI, KEYTRUDA, ZEJULA, CABOMETYX, Fabhalta, CALQUENCE, LYNPARZA.
Industry payments across TX — which companies pay providers there.
